Safety of erlotinib treatment in outpatients with previously treated non-small-cell lung cancer in Japan

被引：0
|
作者：
Hiroki Nagai
Shiro Tanaka
Miyuki Niimi
Nanae Seo
Takahiko Sasaki
Hiroshi Date
Michiaki Mishima
Hiroyasu Yasuda
Kazuhiro Yanagihara
机构：
[1] Outpatient Oncology Unit,Department of Respiratory Medicine, Graduate School of Medicine
[2] Kyoto University Hospital,Department of Clinical Trial Design and Management, Translational Research Center
[3] Kyoto University,Department of Respiratory Medicine
[4] Kyoto University Hospital,Department of Thoracic Surgery, Graduate School of Medicine
[5] Tohoku University School of Medicine,Department of Clinical Application
[6] Kyoto University,Department of Translational Clinical Oncology, Graduate School of Medicine
[7] Tohoku University Translational Research Center,undefined
[8] Kyoto University,undefined
来源：
International Journal of Clinical Oncology | 2011年 / 16卷
关键词：
Erlotinib; Epidermal growth factor receptor; Epidermal growth factor receptor–tyrosine kinase inhibitor; Adverse events; Non-small-cell lung cancer; Japanese outpatients;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [11] Erlotinib in non-small-cell lung cancer
    Gridelli, Cesare
    Rossi, Antonio
    Malone, Paolo
    Colantuoni, Giuseppe
    Del Gaizo, Filomena
    Ferrara, Carmine
    Nicolella, Dario
    Guerriero, Ciro
    EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (15) : 2579 - 2592
  • [12] EVEROLIMUS PLUS ERLOTINIB VERSUS ERLOTINIB ALONE IN PREVIOUSLY TREATED PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
    Bennouna, J.
    Besse, B.
    Leighl, N. B.
    Blais, N.
    Traynor, A. M.
    Papadimitrakopoulou, V.
    Klimovsky, J.
    Jappe, A.
    Jehl, V.
    Johnson, B. E.
    ANNALS OF ONCOLOGY, 2010, 21 : 140 - 140
  • [13] A cost utility analysis of erlotinib in patients with previously treated advanced non-small-cell lung cancer (NSCLC)
    Bradbury, P. A.
    Jang, R.
    Isogai, P.
    Mittmann, N.
    Evans, W.
    Shepherd, F. A.
    Leighl, N. B.
    Ng, R.
    VALUE IN HEALTH, 2008, 11 (03) : A72 - A72
  • [14] Role of Crizotinib in previously treated non-small-cell lung cancer
    Gupta, Sunil Kumar
    SOUTH ASIAN JOURNAL OF CANCER, 2014, 3 (02) : 138 - 140
  • [15] Survival outcomes in patients with non-small-cell lung cancer treated with erlotinib
    McGrath, Alexandria C.
    Sandhu, Geeta
    Walpole, Euan
    McCaffrey, Elizabeth
    Hollingworth, Samantha A.
    ANTI-CANCER DRUGS, 2018, 29 (08) : 786 - 790
  • [16] Erlotinib or Gefitinib for Non-Small-Cell Lung Cancer
    Yusuf, Syed W.
    Kim, Peter
    Durand, Jean-Bernard
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (24): : 2367 - 2367
  • [17] Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer
    Besse, B.
    Leighl, N.
    Bennouna, J.
    Papadimitrakopoulou, V. A.
    Blais, N.
    Traynor, A. M.
    Soria, J. -C.
    Gogov, S.
    Miller, N.
    Jehl, V.
    Johnson, B. E.
    ANNALS OF ONCOLOGY, 2014, 25 (02) : 409 - 415
  • [18] Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
    Natale, Ronald B.
    Thongprasert, Sumitra
    Greco, F. Anthony
    Thomas, Michael
    Tsai, Chun-Ming
    Sunpaweravong, Patrapim
    Ferry, David
    Mulatero, Clive
    Whorf, Robert
    Thompson, Joyce
    Barlesi, Fabrice
    Langmuir, Peter
    Gogov, Sven
    Rowbottom, Jacqui A.
    Goss, Glenwood D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (08) : 1059 - 1066
  • [19] Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non-Small-Cell Lung Cancer
    Sequist, Lecia V.
    von Pawel, Joachim
    Garmey, Edward G.
    Akerley, Wallace L.
    Brugger, Wolfram
    Ferrari, Dora
    Chen, Yinpu
    Costa, Daniel B.
    Gerber, David E.
    Orlov, Sergey
    Ramlau, Rodryg
    Arthur, Susan
    Gorbachevsky, Igor
    Schwartz, Brian
    Schiller, Joan H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (24) : 3307 - 3315
  • [20] Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
    Rogado, J.
    Pacheco-Barcia, V.
    Fenor De la Maza, M. D.
    Serra, J. M.
    Toquero, P.
    Vera, B.
    Obispo, B.
    Mondejar, R.
    Ballesteros, A.
    Donnay, O.
    Colomer, R.
    Sanchez-Torres, J. M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1915 - S1916
12345